Bard: Reasonable explanation:There are no substantiated rumors about FDA approval for Mesoblast Limited (ASX: MSB) today. The company has not made any announcements about FDA approval, and there is no news on the FDA's website about Mesoblast's products.
However, there has been some speculation on social media and investor forums about the possibility of FDA approval for Mesoblast's products. This speculation is based on the fact that Mesoblast has been granted orphan drug designation for its product MPC-100-IM for the treatment of chronic low back pain. Orphan drug designation is a status granted by the FDA to drugs that treat rare diseases. It provides certain benefits to drug developers, such as tax credits and extended marketing exclusivity.
It is important to note that orphan drug designation does not guarantee FDA approval. However, it does increase the likelihood of approval, as the FDA gives priority to reviewing drugs that treat rare diseases.
If you are interested in investing in Mesoblast, it is important to do your own research and to consult with a financial advisor.
Ann: Trading Halt, page-103
-
- There are more pages in this discussion • 1,248 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |